Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an update.
Faron Pharmaceuticals Ltd has appointed Jurriaan Dekkers as its new Chief Financial Officer, effective December 1, 2025, to support the company’s next growth phase. Dekkers, with over 20 years of experience in biopharma and healthcare, is expected to play a crucial role in advancing Faron’s lead asset, bexmarilimab, as it enters a registrational study, following the retirement of the current CFO, Yrjö Wichmann.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its lead asset, bexmarilimab, is an innovative macrophage-guiding immunotherapy being explored in various oncology settings, aiming to harness the immune system’s power to combat cancer.
See more data about FARN stock on TipRanks’ Stock Analysis page.